Targeted therapy with propranolol and metronomic chemotherapy combination: sustained complete response of a relapsing metastatic angiosarcoma

Banavali, Shripad

doi:10.3332/ecancer.2015.499

Cited by 52 publications

(57 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Banavali and colleagues reported on a case of relapsing metastatic angiosarcoma treated with a combination of metronomic oral low-dose chemotherapy (etoposide and cyclophosphamide), celecoxib and PRO (40 mg twice a day) [81]. The patient showed a complete response after two cycles of therapy.…”

Section: Human Datamentioning

confidence: 99%

“…Although no standard treatment exists, the majority of patients are treated with surgical resection, chemotherapy (doxorubicin or paclitaxel most commonly) and radiotherapy [182]. Given the high unmet needs in this disease, the case reports showing some benefit to patients using PRO in combination with other agents are noteworthy [44, 81, 82], along with responses to propranolol observed in other vascular tumours [41, 183–184]. Clinical trials are urgently required to confirm the efficacy of these combinations with PRO.…”

Section: Our Takementioning

confidence: 99%

See 1 more Smart Citation

Repurposing Drugs in Oncology (ReDO)—Propranolol as an anti-cancer agent

Pantziarka

Bouche

Sukhatme³

et al. 2016

ecancer

View full text Add to dashboard Cite

Propranolol (PRO) is a well-known and widely used non-selective beta-adrenergic receptor antagonist (beta-blocker), with a range of actions which are of interest in an oncological context. PRO displays effects on cellular proliferation and invasion, on the immune system, on the angiogenic cascade, and on tumour cell sensitivity to existing treatments. Both pre-clinical and clinical evidence of these effects, in multiple cancer types, is assessed and summarised and relevant mechanisms of action outlined. In particular there is evidence that PRO is effective at multiple points in the metastatic cascade, particularly in the context of the post-surgical wound response. Based on this evidence the case is made for further clinical investigation of the anticancer effects of PRO, particularly in combination with other agents. A number of trials are on-going, in different treatment settings for various cancers.

show abstract

Section: Human Datamentioning

confidence: 99%

Section: Our Takementioning

confidence: 99%

Repurposing Drugs in Oncology (ReDO)—Propranolol as an anti-cancer agent

Pantziarka

Bouche

Sukhatme³

et al. 2016

ecancer

View full text Add to dashboard Cite

show abstract

“…On the other side, in metronomics, the chemotherapeutic drugs are given in low doses or, at least, in doses lower than the maximum tolerated dose and repurposed drugs, as Cel, are administered with a metronomic schedule in the standard, nontoxic doses. In fact, it has already been demonstrated that metronomic chemotherapy is effective in different types of tumors and it is endowed of a low toxicity profile [26][27][28][29][30][31][32][33][34][35] b ringing about no deterioration of patients' QoL.…”

Section: Discussionmentioning

confidence: 99%

Quality of Life in Patients with Metastatic Breast Cancer Treated with Metronomic Chemotherapy

et al. 2016

View full text Add to dashboard Cite

Aim:The objective of the study was to detect changes in quality of life (QoL) in metastatic breast cancer patients treated with metronomic chemotherapy with daily low doses of cyclophosphamide and celecoxib. Material & methods: Patients included in a Phase II trial, treated with metronomic cyclophosphamide and celecoxib were included in the QoL study. Assessment of QoL was carried out every 2 months by the Functional Assessment of Cancer Therapy Breast (FACT-B) questionnaire, Brief Pain Inventory and Eastern Cooperative Oncologic Group scale. Data were analyzed at three time points: baseline (BL); middle of treatment (MT); and end of treatment (ET). Results: A total of 20 patients were included. All patients were heavily pretreated. Treatment showed a good and safe therapeutic profile. With FACT-B questionnaire, no significant differences were observed during the response period (BL-MT). However, a significant increase was observed in the Emotional wellbeing and Additional concerns axes, when the last time point was included in the analysis (BL-MT-ET). A significant decrease in the proportion of patients with pain was found when comparing BL with ET (p = 0.046). The assessment with Eastern Cooperative Oncologic Group scale showed that 26.7% (4/15) of the patients improved their functional status and 40% (6/15) showed no changes, while 33.3% (5/10) worsened it. Conclusion: Patients treated metronomically for several months did not worsen their QoL. A high proportion of patients showed improvement or no changes and there were less patients with pain at the end of the treatment. The quality of life (QoL) is a very common term used in different fields of human health. Therefore, it is very difficult to find a unique definition since it could be related to all aspects of human life [1].In an attempt to define it, it can be said that it is "the perfect balance between well-being and distress" [2,3]. The concept of adaptation to chronic disease is different but it is related to that of QoL; adaptation is the process whereby individuals use conscious awareness and choice to create new human environmental integration [4,5]. Both are good indicators of the evolution of psychological features of cancer patients at different stages of the disease [6]. In oncology QoL is centered in patients' health, and refers to all aspects (general, social, personal, emotional, among others) of 1234RESEaRch aRticlE Perroud, Alasino, Rico et al. future science group the subject and their relationship to the cancer disease and its treatment.The presence of pain is a very complex aspect related to QoL, and it is one of the most difficult symptoms to evaluate and to treat; in many cases pain is caused by the pressure that the tumor exerts on bones and/or nerves, and also it could be caused by cancer treatment. One of the barriers in pain treatment is the inadequate measurement and assessment of pain. An optimal management includes the evaluation of intensity, characteristics and interference with daily habits and life style [7,8].The meas...

show abstract

“…In 2015, Banavali et al [28] reported a case of 69-year-old woman with relapsing metastatic skin angiosarcoma treated with a combination of metronomic chemotherapy and nonselective beta-blocker propranolol. The patient was treated with low doses of cyclophosphamide and etoposide along with nonsteroid anti-inflammatory drug (NSAID) celecoxib and propranolol.…”

Section: Discussionmentioning

confidence: 99%

Primary Angiosarcoma of the Spleen: Rare Diagnosis with Atypical Clinical Course

Kohutek

Badik

Bystricky

2016

Case Reports in Oncological Medicine

View full text Add to dashboard Cite

Primary angiosarcoma of the spleen is a rare diagnosis with poor prognosis. Morphologically, it demonstrates conventional blood vessel differentiation. We present a case of 65-year-old female who underwent radical splenectomy for primary angiosarcoma of the spleen. After three-year disease-free interval, she was diagnosed with bone-only metastatic disease. Palliative radiotherapy and bisphosphonates kept her disease reasonably stable for another four years. After development of lung metastases, six cycles of single agent doxorubicin kept her progression-free for six years. Upon further progression in lungs, thirteen years after original diagnosis, lung biopsy confirmed metastatic splenic angiosarcoma in the lungs. She started weekly paclitaxel chemotherapy. Although splenic angiosarcoma generally carries grave prognosis, some patients may enjoy prolonged periods of disease stabilization. Durable benefit can be achieved in some patients with multimodality management. We review the literature focusing on systemic treatment for this rare tumor.

show abstract

Targeted therapy with propranolol and metronomic chemotherapy combination: sustained complete response of a relapsing metastatic angiosarcoma

Cited by 52 publications

References 13 publications

Repurposing Drugs in Oncology (ReDO)—Propranolol as an anti-cancer agent

Repurposing Drugs in Oncology (ReDO)—Propranolol as an anti-cancer agent

Quality of Life in Patients with Metastatic Breast Cancer Treated with Metronomic Chemotherapy

Primary Angiosarcoma of the Spleen: Rare Diagnosis with Atypical Clinical Course

Contact Info

Product

Resources

About